Shortened megakaryocyte-platelet regeneration time in young survivors of myocardial infarction

Hamsten, Anders; Svensson, Jan; Walldius, G; Szamosi, Alfred; Fairé, Ulf dé

doi:10.1016/0002-8703(85)90005-5

Cited by 15 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phasic increases in thromboxane synthesis have been seen in patients with unstable angina and other conditions associated with increased platelet turnover, such as diabetes mellitus, pre-eclampsia, and advanced coronary artery disease. [21][22][23] Furthermore, the concept of enhanced platelet recovery was recently discussed in relation to the PED Shield. 6 Although aspirin could be used in conjunction with coated devices, such as the p48_HPC, the potential for inadequate antiplatelet activity was considered too great especially because these were the first cases evaluated in human patients.…”

Section: Demographicsmentioning

confidence: 99%

The p48_HPC antithrombogenic flow diverter: initial human experience using single antiplatelet therapy

et al. 2019

View full text Add to dashboard Cite

The p48 is a low-profile, intermediate-porosity flow diverter. phenox GmbHtrademarked hydrophilic polymer coating (pHPC) is a hydrophilic coating that has been shown in vitro to reduce the thrombogenicity of nitinol device surfaces. We performed the present study to determine whether the p48_HPC can be implanted using prasugrel alone. Methods: We retrospectively identified all patients who were treated with the p48_HPC from January 2017 to December 2018 (n ¼ 5) and underwent single antiplatelet therapy (SAPT) with prasugrel. P2Y12 inhibition was confirmed by the VerifyNow assay. The occurrence of thromboembolic and haemorrhagic complications was recorded alongside the occlusion rates of the treated aneurysms. Results: All patients achieved adequate occlusion (Raymond-Roy Occlusion Classification I or II) during the follow-up period. No thromboembolic complications occurred. One patient developed a contained haematoma within the Sylvian fissure from the treated aneurysm 2 weeks postoperatively without clinical sequelae. Conclusions: In this small series, no thromboembolic complications occurred in patients treated with the surface modified p48_HPC flow diverter and SAPT. Further studies with longer follow-up periods and larger cohorts should be performed.

show abstract

Section: Demographicsmentioning

confidence: 99%

The p48_HPC antithrombogenic flow diverter: initial human experience using single antiplatelet therapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Newly formed platelets with intact cyclooxygenase activity can be detected as soon as 4 to 6 hours after aspirin ingestion. 10 This platelet turnover is accelerated in certain clinical settings, including diabetes, 29 after cardiac surgery, 30 and after MI, 31,32 and has been associated with aspirin resistance. Interestingly, a recent analysis of patients with stable coronary artery disease taking once-daily aspirin showed that up to 25% of patients had suboptimal platelet inhibition with 24-hour aspirin dosing when analyzed with arachidonic acid-mediated light transmission aggregometry.…”

Section: Mechanisms Of Aspirin Resistancementioning

confidence: 99%

“…57 As mentioned above, platelet turnover appears to be more rapid in patients with acute MI and may partially explain the higher rates of aspirin resistance. 31,32 There is a reduction of large platelets at the time of admission but not during recovery in patients with an acute MI, suggesting that there may be a consumption of large platelets at the time of thrombus formation. 58 ADP levels have been shown to be higher during the acute infarct setting in patients with STEMI, and higher levels correlate with increased platelet aggregation.…”

Section: Post-acsmentioning

confidence: 99%

Aspirin Resistance: Current Status and Role of Tailored Therapy

Grinstein

Cannon

2012

Clinical Cardiology

View full text Add to dashboard Cite

Aspirin is integral in the primary and secondary prevention of coronary artery disease and acute coronary syndrome. Given the high clinical importance of aspirin in the management of coronary artery disease, much attention has been directed towards the concept of “aspirin resistance.” Unfortunately, the term aspirin resistance is ill‐defined in the literature, leading to a large variance in the reported prevalence of this phenomenon. In this review, the current understanding of aspirin resistance is discussed. Commonly used functional and diagnostic tests of platelet function, including their strengths and weakness, are reviewed. We next discuss several proposed mechanisms of aspirin resistance and special high‐risk groups at risk for aspirin treatment failure. We then discuss optimal dosing and diagnostic strategies for those populations at risk for aspirin resistance with a focus on tailored aspirin therapy for high‐risk groups. Finally, future topics of interest in the field of aspirin resistance are considered. Clin. Cardiol. 2012 doi: 10.1002/clc.22031Jonathan Grinstein has no funding, financial relationships, or conflicts of interest to disclose. Christopher P. Cannon receives research grants/support from the following companies: Accumetrics, AstraZeneca, Essentialis, GlaxoSmithKline, Merck, Regeneron, Sanofi, and Takeda. He is also on the advisory board (but funds donated to charity) for Alnylam, Bristol‐Myers Squibb, and Pfizer. He is a Clinical Advisor, equity in Automedics Medical Systems.

show abstract

“…PAI-1 antigen [27] can predict cardiovascular disease, and deserve special interest. We could to 6.9%.…”

Section: Fish Oil (N = 14)mentioning

confidence: 99%

Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy

Myrup

Rossing

Jensen

et al. 2001

Scandinavian Journal of Clinical and Laboratory Investigation

View full text Add to dashboard Cite

show abstract

Shortened megakaryocyte-platelet regeneration time in young survivors of myocardial infarction

Cited by 15 publications

References 29 publications

The p48_HPC antithrombogenic flow diverter: initial human experience using single antiplatelet therapy

The p48_HPC antithrombogenic flow diverter: initial human experience using single antiplatelet therapy

Aspirin Resistance: Current Status and Role of Tailored Therapy

Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy

Contact Info

Product

Resources

About